10-Q: Delcath Systems Reports Q1 2026 Financials, Revenue Up

Delcath Systems, Inc. reported its first quarter 2026 financial results, showing a significant increase in revenue driven by its HEPZATO KIT product.

Summary

• Delcath Systems, Inc. reported its financial results for the first quarter ended March 31, 2026.
• Total revenue increased to $24.99 million, up from $19.78 million in the same period of 2025.
• The increase was primarily driven by the continued commercial expansion and demand for HEPZATO KIT in the United States.
• The company reported a net loss of $1.07 million for the quarter, compared to a net income of $1.07 million in the prior year's quarter.
• As of March 31, 2026, the company had cash and cash equivalents of $41.3 million and short-term investments of $48.0 million, which management believes is sufficient for at least 12 months of operations.
• The company repurchased approximately $9.0 million of its common stock under its $25 million share repurchase program as of March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative sentiment, as revenue growth is positive, but the swing to a net loss and increased operating expenses are concerning.

Positives

• Total revenue increased by 26.3% to $24.99 million for the three months ended March 31, 2026, compared to $19.78 million for the same period in 2025.
• HEPZATO KIT revenue grew to $23.25 million, up from $18.02 million in the prior year's quarter.
• The company has sufficient cash and investments ($89.3 million total) to support operations for at least 12 months.
• The company has approximately $16.0 million remaining under its authorized share repurchase program.

Negatives

• The company reported a net loss of $1.07 million for the three months ended March 31, 2026, a reversal from a net income of $1.07 million in the prior year's quarter.
• Operating expenses increased significantly to $22.90 million from $16.30 million, driven by higher R&D and SG&A costs.
• Research and development expenses increased by 96.2% to $9.82 million, primarily due to expanding the clinical team and ongoing Phase 2 trials.
• Selling, general, and administrative expenses increased by 15.6% to $13.07 million, due to commercial expansion activities.

Risks

• The company is subject to risks common to the biopharmaceutical industry, including product development, commercialization, regulatory approvals, and significant competition.
• Geopolitical events, global health outbreaks, and supply chain disruptions could impact manufacturing, clinical trials, and costs.
• The company's revenue is generated from a concentrated group of customers, and a payment delay, dispute, or reduction in ordering activity by a significant customer could adversely affect operating cash flow.
• The company may face challenges in obtaining regulatory approval for additional indications and in achieving broad adoption of its products by physicians and consumers.
• The company's ability to successfully source components and manufacture its products is critical.

Future Outlook

The company expects its research and development expenses to increase due to costs associated with completing Phase 2 clinical trials for mCRC and mBC, exploring new indications, and potential applications of its therapies. Management believes current cash and investments are sufficient to support operations for at least 12 months.

Management Comments

• The increase in total revenue for the three months ended March 31, 2026 compared to the same period in 2025 was due to the continued commercial expansion and demand of HEPZATO in the United States.
• The increase in research and development expenses for the three months ended March 31, 2026 compared to the same period in 2025 is due to the continued costs associated with expanding the clinical team, including the base and supplemental wages related to an increase in headcount, and continuation of the Phase 2 clinical trials evaluating HEPZATO in combination with standard of care for mCRC and mBC.
• For the three months ended March 31, 2026 compared to the same period in 2025, selling, general and administrative expenses increased due to continued commercial expansion activities including marketing-related travel expenses and additional personnel on the commercial team.

Industry Context

StockSavvy.ai notes that Delcath Systems is operating in the competitive interventional oncology market, focusing on liver-directed therapies. The reported revenue growth for HEPZATO KIT aligns with the increasing adoption of targeted therapies for difficult-to-treat cancers, though the company's net loss highlights the significant R&D investment required in this sector.

Comparison to Industry Standards

• The reported revenue growth of 26.3% for the quarter is strong, particularly for a company in the biopharmaceutical sector commercializing a novel therapy. However, direct comparisons are difficult without specific segment data from competitors.
• The net loss of $1.07 million is not unusual for companies in the clinical development and early commercialization phase of drug/device combinations, where significant R&D and SG&A expenses are incurred.
• The company's cash position of $89.3 million in cash and short-term investments is a key positive, providing runway for ongoing clinical trials and commercialization efforts, which is crucial in an industry with long development cycles and high capital requirements.

Legal Proceedings

• The medac Matter: Delcath Systems Ltd. is involved in a settlement related to a license, supply, and marketing agreement. As of March 31, 2026, $0.8 million was estimated as the remaining fair value of the settlement, with $0.6 million recorded as other liabilities, non-current and $0.2 million as accounts payable.

Stakeholder Impact

• Shareholders: The swing to a net loss and increased operating expenses may impact investor sentiment. The share repurchase program could provide some support to the stock price.
• Employees: Increased R&D and SG&A expenses suggest continued investment in personnel and operations, potentially leading to growth opportunities.
• Customers (Hospitals/Treatment Centers): Continued commercial expansion of HEPZATO is positive for access to treatment. Concentration of credit risk with a few large customers could pose a risk if payment terms are not met.
• Suppliers: The company has committed to purchasing $2.5 million of melphalan in 2026, indicating ongoing demand and stable relationships with key suppliers.

Next Steps

• Continue Phase 2 clinical trials for HEPZATO in liver-dominant mCRC and HER2-negative mBC.
• Generate clinical data to support increased clinical adoption and reimbursement for CHEMOSAT in Europe and HEPZATO in the United States.
• Explore potential applications of HEPZATO for other liver cancers.
• Continue commercial expansion and demand generation for HEPZATO in the United States.
• Monitor and manage supply chain risks through inventory and multiple suppliers.
• Continue share repurchases under the authorized program as market conditions permit.

Key Dates

Recommendation

While revenue growth is positive, the shift to a net loss and significant increase in operating expenses warrant caution. The company's cash position provides runway, but the path to profitability remains uncertain. Investors should monitor clinical trial progress and commercial adoption trends.

Keywords

Delcath Systems, 10-Q, HEPZATO KIT, CHEMOSAT, Interventional Oncology, Uveal Melanoma, Metastatic Colorectal Cancer, Metastatic Breast Cancer, Clinical Trials, Revenue, Net Loss, SEC Filing